Ibio Inc
Change company Symbol lookup
Select an option...
IBIO Ibio Inc
JPS Nuveen Preferred & Income Securities Fund
EFSC Enterprise Financial Services Corp
CYPS Cyclo3pss Corp
CXW CoreCivic Inc
STM STMicroelectronics NV
NYT New York Times Co
SOS Sos Ltd
DDOC DERMADOCTOR, INC.
CLOV Clover Health Investments Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

Closing Price
$1.70
Day's Change
0.10 (6.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.76
Day's Low
1.53
Volume
(Heavy Day)
Volume:
96,296

10-day average volume:
50,426
96,296

Alphabet stock price target cut to $114 from $125 at BofA Securities

9:49 am ET October 4, 2022 (MarketWatch)
Print
	

(END) Dow Jones Newswires

October 04, 2022 09:49 ET (13:49 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.